RT Journal Article
SR Electronic
T1 Biologics in severe asthma: the role of real-world evidence from registries
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 210278
DO 10.1183/16000617.0278-2021
VO 31
IS 164
A1 Giovanni Paoletti
A1 Jack Pepys
A1 Marta Casini
A1 Danilo Di Bona
A1 Enrico Heffler
A1 Celine Y.Y. Goh
A1 David B. Price
A1 Giorgio Walter Canonica
YR 2022
UL http://err.ersjournals.com/content/31/164/210278.abstract
AB Asthma is one of the most common noncommunicable diseases; in the majority of patients it is well controlled with inhaled bronchodilators and inhaled corticosteroids, but the management of severe asthma has been a significant challenge historically. The introduction of novel biologic drugs in the past few decades has revolutionised the field, presenting physicians with a variety of biologic drugs with different mechanisms for the treatment of severe asthma.It is of crucial importance to evaluate the effectiveness of these drugs by following their “real-life” effectiveness rather than relying solely on their efficacy, established in carefully designed clinical trials, which therefore do not necessarily match the profile of the real-life patient. Understanding the actual effectiveness of the specific drugs in real-life patients is a crucial part of tailoring the right drugs to the right patients. Registries serve as an important tool in obtaining real-life evidence, since they are in effect observational studies, following the entire patient population.Data on long-term efficacy and safety of biologics in severe asthma cannot be obtained by RCTs alone. Real-life studies should be a valuable source of this kind of information. https://bit.ly/3vM8AaD